MENA Pharmaceutical Market Data 2026
Comprehensive market intelligence on the pharmaceutical landscape across the Middle East and North Africa. Country-by-country breakdown of market size, growth rates, per-capita spending, regulatory bodies, and therapeutic area trends.
Last updated: February 2026 · Sources: BioNixus MEA Market Report, Grand View Research, WHO EMRO, national health authority filings
Cite this data
BioNixus. "MENA Pharmaceutical Market Data 2026." BioNixus Healthcare Market Research, Feb. 2026, https://www.bionixus.com/mena-pharma-market-data.
Licensed under CC BY 4.0 — free to share and adapt with attribution.
$33.9B
Total MEA pharma market (Q3 2024)
12.2%
Year-over-year growth
$81.6B
Projected market value by 2030
5.1%
CAGR 2025–2030
GCC & North Africa: Market Data by Country
Pharma market value, year-over-year growth, per-capita pharmaceutical spending, and primary regulatory authority for each major MENA market.
Saudi Arabia
Market Value
$12.4 B
YoY Growth
11.1%
Pharma / Capita
$336
Regulator
SFDA
Key insight: Largest GCC market — 36.7% of MEA total value sales
View full Saudi Arabia pharma industry guideUnited Arab Emirates
Market Value
$4.5 B
YoY Growth
17.5%
Pharma / Capita
$446
Regulator
MOHAP / DHA / DOH
Key insight: Fastest-growing GCC market; medical tourism hub
Egypt
Market Value
$5.8 B
YoY Growth
9.2%
Pharma / Capita
$53
Regulator
EDA
Key insight: Largest population in MENA; strong generics manufacturing base
View full Egypt pharma industry guideKuwait
Market Value
$1.2 B
YoY Growth
8.4%
Pharma / Capita
$245
Regulator
MOH
Key insight: 95% of pharmaceuticals imported; government-funded healthcare
View full Kuwait pharma industry guideQatar
Market Value
$0.9 B
YoY Growth
12.3%
Pharma / Capita
$333
Regulator
MOPH
Key insight: Highest healthcare spending per capita in MENA
View full Qatar pharma industry guideBahrain
Market Value
$0.4 B
YoY Growth
7.8%
Pharma / Capita
$267
Regulator
NHRA
Key insight: First GCC country to approve biosimilar pathway
View full Bahrain pharma industry guideOman
Market Value
$0.7 B
YoY Growth
6.9%
Pharma / Capita
$152
Regulator
MOH
Key insight: Vision 2040 driving local manufacturing expansion
View full Oman pharma industry guideMarket Structure & Distribution
How pharmaceuticals are distributed and who holds market share across the MENA region.
Distribution Channels
$23.3B in value sales
$10.6B in value sales
Company Origin Market Share
Growing at 11.6% YoY
Growing at 13.1% YoY (volume declining)
Product Composition
Top Pharma Companies in MEA
- 1Novartis
- 2Sanofi
- 3GSK
- ★Eli Lilly — fastest growth among top 10 at 100.6% YoY
Therapeutic Area Growth in MENA
Estimated compound annual growth rates and key market drivers for major therapeutic areas across the MENA pharmaceutical market.
Oncology
14.2% CAGRRising cancer prevalence, immuno-oncology adoption, access to targeted therapies
Diabetes & Endocrinology
12.8% CAGRMENA has highest global diabetes prevalence (~16.2%); GLP-1 adoption accelerating
Cardiovascular
9.1% CAGRHypertension under-diagnosis in MENA; growing preventive cardiology programmes
Immunology & Rheumatology
11.5% CAGRBiologic uptake in RA, psoriasis; biosimilar competition increasing
Respiratory
8.7% CAGRAsthma & COPD awareness campaigns; dust/pollution in Gulf states
Neurology
10.3% CAGRMS prevalence higher than global average in parts of MENA; migraine biologic launches
Rare Diseases
15.1% CAGRConsanguinity-related genetic conditions; orphan drug legislation evolving in GCC
Infectious Disease
7.4% CAGRHepatitis B/C programmes, TB in North Africa, vaccine infrastructure expansion
Key Growth Drivers
Macro-level factors fuelling pharmaceutical market expansion across the MENA region.
Chronic Disease Burden
MENA has the highest global diabetes prevalence (~16.2%) and rapidly rising cardiovascular, oncology, and respiratory disease rates driven by urbanisation, dietary changes, and ageing populations.
Government Health Investment
Saudi Vision 2030, UAE Health Agenda, and Egypt's Universal Health Insurance programme are driving multi-billion dollar healthcare infrastructure expansion and pharmaceutical self-sufficiency targets.
Local Manufacturing Push
GCC governments are incentivising local pharma manufacturing through priority regulatory review, preferential procurement (60%+ of government contracts), tax benefits, and extended market exclusivity.
Regulatory Modernisation
SFDA, MOHAP, and EDA are aligning with ICH guidelines, reducing approval timelines and creating more predictable pathways for innovator and biosimilar products.
Population Growth & Urbanisation
MENA population projected to exceed 600M by 2030. Urbanisation rates above 80% in GCC drive demand for specialised care and branded pharmaceuticals.
Digital Health Adoption
COVID-19 accelerated telehealth, e-pharmacy, and digital therapeutics adoption across MENA, creating new channels for pharmaceutical engagement and patient monitoring.
Data Sources & Methodology
This data page aggregates publicly available information from the following sources:
- BioNixus Middle East & Africa Pharmaceutical Market Quarterly Report, Q3 2024
- Grand View Research — Middle East & Africa Pharmaceutical Market Size & Outlook, 2025–2030
- Ken Research — Middle East Pharmaceuticals Market Report, 2025–2030
- WHO Eastern Mediterranean Regional Office (EMRO) country profiles
- National regulatory authority filings: SFDA, MOHAP, DHA, DOH, EDA, NHRA
- BioNixus proprietary research from 500+ physician surveys across GCC (2024–2025)
Per-capita pharmaceutical spending figures are estimated by BioNixus based on market value divided by mid-year population estimates. Growth rates are year-over-year unless otherwise stated. All values in USD.
Need Deeper Market Intelligence?
BioNixus delivers custom pharmaceutical market research across MENA and Europe — quantitative physician surveys, competitive intelligence, market access strategy, and KOL mapping.